Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Uses, Dosage, Side Effects and more
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2. It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906) with an expected completion in December 2020. The study will evaluate antibody response in healthy patients between the ages of 18 and 60 who will receive one of three study doses, with follow-up taking place at weeks 2 and 4 and months 3 and 6 post-vaccination.
| Attribute | Details |
|---|---|
| Trade Name | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) |
| Generic | Ad5-nCoV |
| Ad5-nCoV Other Names | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
